articleScience Translational MedicineApr 15, 2015Closed access

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

Johns Hopkins University · Johns Hopkins Medicine · +4 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Stimulator of interferon genes (STING) is a cytosolic receptor that senses both exogenous and endogenous cytosolic cyclic dinucleotides (CDNs), activating TBK1/IRF3 (interferon regulatory factor 3), NF-κB (nuclear factor κB), and STAT6 (signal transducer and activator of transcription 6) signaling pathways to induce robust type I interferon and proinflammatory cytokine responses. CDN ligands were formulated with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing cellular cancer vaccines--termed STINGVAX--that demonstrated potent in vivo antitumor efficacy in multiple therapeutic models of established cancer. We found that rationally designed synthetic CDN derivative molecules, including one…

Citation impact

696
total citations
FWCI
23.33
Percentile
100%
References
48
Citations per year

Authors

19

Topics & keywords

Keywords
  • Blockade
  • Agonist
  • Medicine
  • Cancer
  • Sting
  • Cancer research
  • Pharmacology
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding